4.8 (310) In stock
Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.
Targeted therapeutic options and future perspectives for HER2-positive breast cancer. - Abstract - Europe PMC
Frontiers Cutaneous manifestations associated with immune checkpoint inhibitors
Figure 1 from Lapatinib for advanced or metastatic breast cancer.
Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis, Systematic Reviews
PDF) Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
PDF) Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial
